At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the futur...
Clinical experience over decades and numerous retrospective and, recently, also prospective studies ...
<div><p>Background & aims</p><p>Prophylactic injections of factor VIII reduce the incidence of bleed...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Prophylactic treatment of haemophilia has been gaining acceptance as the optimal therapeutic option ...
The hallmark of severe haemophilia, defined as a circulating level of factor (F) VIII (haemophilia A...
Prophylaxis is defined as the regular administration of clotting factor concentrates to prevent blee...
Data from prospective studies clearly demonstrate the efficacy of prophylactic treatment of haemophi...
Prophylaxis entails long-term continuous intravenous administration of concentrates of the deficient...
The aim of the thesis was to increase cost-effectiveness in prophylactic treatment of haemophilia. P...
Background Prophylaxis is the gold standard for the treatment of children with severe hemophilia. In...
Summary: Long-term, continuous prophylaxis for haemophilia began at a modest scale during the 1950s ...
Prophylactic injections of factor VIII reduce the incidence of bleeds and slow the development of jo...
To summarize, prophylactic treatment of hemophilia begun at an early age has been gaining acceptance...
Haemophilia A is a sex-linked disorder characterised chiefly by recurrent, spontaneous joint and mus...
Initiating prophylactic treatment at an early age is considered to be the optimal form of therapy fo...
Clinical experience over decades and numerous retrospective and, recently, also prospective studies ...
<div><p>Background & aims</p><p>Prophylactic injections of factor VIII reduce the incidence of bleed...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Prophylactic treatment of haemophilia has been gaining acceptance as the optimal therapeutic option ...
The hallmark of severe haemophilia, defined as a circulating level of factor (F) VIII (haemophilia A...
Prophylaxis is defined as the regular administration of clotting factor concentrates to prevent blee...
Data from prospective studies clearly demonstrate the efficacy of prophylactic treatment of haemophi...
Prophylaxis entails long-term continuous intravenous administration of concentrates of the deficient...
The aim of the thesis was to increase cost-effectiveness in prophylactic treatment of haemophilia. P...
Background Prophylaxis is the gold standard for the treatment of children with severe hemophilia. In...
Summary: Long-term, continuous prophylaxis for haemophilia began at a modest scale during the 1950s ...
Prophylactic injections of factor VIII reduce the incidence of bleeds and slow the development of jo...
To summarize, prophylactic treatment of hemophilia begun at an early age has been gaining acceptance...
Haemophilia A is a sex-linked disorder characterised chiefly by recurrent, spontaneous joint and mus...
Initiating prophylactic treatment at an early age is considered to be the optimal form of therapy fo...
Clinical experience over decades and numerous retrospective and, recently, also prospective studies ...
<div><p>Background & aims</p><p>Prophylactic injections of factor VIII reduce the incidence of bleed...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...